Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 29:2020:9638763.
doi: 10.1155/2020/9638763. eCollection 2020.

Protective Role of Glutathione and Nitric Oxide Production in the Pathogenesis of Pterygium

Affiliations

Protective Role of Glutathione and Nitric Oxide Production in the Pathogenesis of Pterygium

Fidelina Parra et al. J Ophthalmol. .

Abstract

Objective: In the pathogenesis of pterygium, the protective role of glutathione and nitric oxide production is unclear. These are important factors for homeostasis in the redox state of cells. The aim of this study was to determine the levels of these and related parameters in pterygium tissue. Patients and Methods. The study sample consisted of 120 patients diagnosed with primary or recurrent pterygium. Five groups of tissue samples were examined: control, primary pterygium, recurrent pterygium, and two groups of primary pterygium given a one-month NAC presurgery treatment (topical or systemic). The levels of endothelial nitric oxide synthase (eNOS), nitric oxide (NO), 3-nitrotyrosine (3NT), reduced and oxidized glutathione (GSH and GSSG), and catalase (CAT) were evaluated in tissue homogenates.

Results: Compared with the control, decreased levels of eNOS, NO, and 3-nitrotyrosine as well as the degree of oxidation of GSH (GSSG%) were observed in primary and recurrent pterygium. 3-Nitrotyrosine and GSSG% were reduced in the other pterygium groups. GSH and CAT were enhanced in recurrent pterygium and systemic-treated primary pterygium but were unchanged for topical-treated primary pterygium. There was a strong positive correlation of eNOS with NO and 3NT, GSSG% with NO and 3NT, and GSH with GSSG and CAT. Women showed a higher level of GSH and catalase in primary pterygium, whereas a lower level of GSH and a higher level of NO in recurrent pterygium.

Conclusion: The results are congruent with the following proposed sequence of events leading to a protective response of the organism during the pathogenesis of primary pterygium: a decreased level of eNOS provokes a decline in the level of NO in pterygium tissue, which then leads to reduced S-nitrosylation of GSH or other thiols and possibly to the modulation of the intracellular level of GSH through synthesis and/or mobilization from other tissues.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Oxidant/antioxidant response in all patients regardless of gender (mean ± SD). Levels of reduced (a) and oxidized GSH (b), CAT (c), degree of GSH oxidation (d), NO (e), and 3-nitrotyrosine (f) in the control group (C), primary pterygium (P), recurrent pterygium (R), and primary pterygium with systemic (Ps) or topical (Pt) pretreatment in all patients regardless of gender. p < 0.05 and ∗∗p < 0.01 compared with group C. #p < 0.05 and ##p < 0.01 compared with the primary pterygium group. &p < 0.05 and &&p < 0.01 compared with group R. $$p < 0.01 compared groups with treatments.
Figure 2
Figure 2
Response of eNOS in all patients regardless of gender. Levels of eNOS activity in the control group (C), primary pterygium (P), recurrent pterygium (R), and primary pterygium with systemic (Ps) or topical (Pt) pretreatment in all patients regardless of gender. p < 0.05 and ∗∗p < 0.01 compared with group C. #p < 0.05 and ##p < 0.01 compared with primary pterygium group. &p < 0.05 and &&p < 0.01 compared with group R. $p < 0.05 compared groups with treatments.

Similar articles

Cited by

References

    1. Chui J., Girolamo N. D., Wakefield D., Coroneo M. T. The pathogenesis of pterygium: current concepts and their therapeutic implications. The Ocular Surface. 2008;6(1):24–43. doi: 10.1016/s1542-0124(12)70103-9. - DOI - PubMed
    1. Malozhen S. A., Trufanov S. V., Krakhmaleva D. A. Pterygium: etiology, pathogenesis, treatment. Vestnik Oftal’mologii. 2017;133(5):76–83. doi: 10.17116/oftalma2017133576-83. - DOI - PubMed
    1. Saccà S. C., Roszkowska A. M., Izzotti A. Environmental light and endogenous antioxidants as the main determinants of non-cancer ocular diseases. Mutation Research/Reviews in Mutation Research. 2013;752(2):153–171. doi: 10.1016/j.mrrev.2013.01.001. - DOI - PubMed
    1. Coroneo M. T., Di Girolamo N., Wakefield D. The pathogenesis of pterygia. Current Opinion in Opthalmology. 1999;10(4):282–288. doi: 10.1097/00055735-199908000-00011. - DOI - PubMed
    1. Hilgers J. H. C. Pterygium: its incidence, heredity and etiology. American Journal of Ophthalmology. 1960;50(4):635–644. doi: 10.1016/0002-9394(60)90245-2. - DOI - PubMed

LinkOut - more resources